Literature DB >> 23468416

Systematic engineering of uniform, highly efficient, targeted and shielded viral-mimetic nanoparticles.

Zahra Karjoo1, Helen O McCarthy, Parin Patel, Faranak Salman Nouri, Arash Hatefi.   

Abstract

In the past decades, numerous types of nanomedicines have been developed for the efficient and safe delivery of nucleic acid-based drugs for cancer therapn>y. Given that the destination sites for nucleic acid-based drugs are inside n>an class="Disease">cancer cells, delivery systems need to be both targeted and shielded in order to overcome the extracellular and intracellular barriers. One of the major obstacles that has hindered the translation of nanotechnology-based gene-delivery systems into the clinic has been the complexity of the design and assembly processes, resulting in non-uniform nanocarriers with unpredictable surface properties and efficiencies. Consequently, no product has reached the clinic yet. In order to address this shortcoming, a multifunctional targeted biopolymer is genetically engineered in one step, eliminating the need for multiple chemical conjugations. Then, by systematic modulation of the ratios of the targeted recombinant vector to PEGylated peptides of different sizes, a library of targeted-shielded viral-mimetic nanoparticles (VMNs) with diverse surface properties are assembled. Through the use of physicochemical and biological assays, targeted-shielded VMNs with remarkably high transfection efficiencies (>95%) are screened. In addition, the batch-to-batch variability of the assembled targeted-shielded VMNs in terms of uniformity and efficiency is examined and, in both cases, the coefficient of variation is calculated to be below 20%, indicating a highly reproducible and uniform system. These results provide design parameters for engineering uniform, targeted-shielded VMNs with very high cell transfection rates that exhibit the important characteristics for in vivo translation. These design parameters and principles could be used to tailor-make and assemble targeted-shielded VMNs that could deliver any nucleic acid payload to any mammalian cell type.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  gene delivery; gene therapy; nanomedicine; nanoparticles; viral mimetics

Mesh:

Year:  2013        PMID: 23468416      PMCID: PMC5222681          DOI: 10.1002/smll.201300077

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  28 in total

1.  Biophysical characterization of the DNA binding and condensing properties of adenoviral core peptide mu.

Authors:  Michael Keller; Toshiaki Tagawa; Monika Preuss; Andrew D Miller
Journal:  Biochemistry       Date:  2002-01-15       Impact factor: 3.162

2.  Structure and function correlation in histone H2A peptide-mediated gene transfer.

Authors:  Danuta Balicki; Christopher D Putnam; Puthupparampil V Scaria; Ernest Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  Ultrahigh nanoparticle stability against salt, pH, and solvent with retained surface accessibility via depletion stabilization.

Authors:  Xu Zhang; Mark R Servos; Juewen Liu
Journal:  J Am Chem Soc       Date:  2012-06-06       Impact factor: 15.419

4.  Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells.

Authors:  Sriramchandra S Mangipudi; Brenda F Canine; Yuhua Wang; Arash Hatefi
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

5.  Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

Authors:  Anna Orlova; Mikaela Magnusson; Tove L J Eriksson; Martin Nilsson; Barbro Larsson; Ingmarie Höidén-Guthenberg; Charles Widström; Jörgen Carlsson; Vladimir Tolmachev; Stefan Ståhl; Fredrik Y Nilsson
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

6.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

7.  Engineering a clinically-useful matrix for cell therapy.

Authors:  Glenn D Prestwich
Journal:  Organogenesis       Date:  2008-01       Impact factor: 2.500

8.  The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

Authors:  Mark E Davis
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

9.  Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells.

Authors:  Brenda F Canine; Yuhua Wang; Arash Hatefi
Journal:  J Control Release       Date:  2009-04-18       Impact factor: 9.776

10.  Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing.

Authors:  Jie Gao; Jing Sun; Huimei Li; Wei Liu; Yang Zhang; Bohua Li; Weizhu Qian; Hao Wang; Jianming Chen; Yajun Guo
Journal:  Biomaterials       Date:  2009-12-24       Impact factor: 12.479

View more
  5 in total

1.  Production of low-expressing recombinant cationic biopolymers with high purity.

Authors:  Xuguang Chen; Alireza Nomani; Niket Patel; Arash Hatefi
Journal:  Protein Expr Purif       Date:  2017-03-16       Impact factor: 1.650

2.  Development of a Recombinant Multifunctional Biomacromolecule for Targeted Gene Transfer to Prostate Cancer Cells.

Authors:  Arash Hatefi; Zahra Karjoo; Alireza Nomani
Journal:  Biomacromolecules       Date:  2017-08-24       Impact factor: 6.988

3.  Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides.

Authors:  Faranak S Nouri; Xing Wang; Xuguang Chen; Arash Hatefi
Journal:  Pharm Res       Date:  2015-03-31       Impact factor: 4.200

Review 4.  Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells.

Authors:  Xuguang Chen; Alireza Nomani; Niket Patel; Faranak S Nouri; Arash Hatefi
Journal:  Biomaterials       Date:  2017-10-20       Impact factor: 12.479

5.  RALA-mediated delivery of FKBPL nucleic acid therapeutics.

Authors:  Rachel Bennett; Anita Yakkundi; Hayley D McKeen; Lana McClements; Thomas J McKeogh; Cian M McCrudden; Kenneth Arthur; Tracy Robson; Helen O McCarthy
Journal:  Nanomedicine (Lond)       Date:  2015-09-30       Impact factor: 6.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.